# 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

> **NCT02448225** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 46 (actual)

## Conditions studied

- Lung Carcinoma
- Solitary Pulmonary Nodule
- Cigarette Smoking Behavior

## Interventions

- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Computed Tomography
- **RADIATION:** fluorodeoxyglucose F-18
- **DRUG:** Fluorine F 18 L-glutamate Derivative BAY94-9392
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Positron Emission Tomography (PET)

## Key facts

- **NCT ID:** NCT02448225
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-16
- **Primary completion:** 2021-08-02
- **Final completion:** 2022-10-10
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02448225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02448225, "18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02448225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*